Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502396 · ClinicalTrials.gov registry record
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 265
- Enrollment target
NCT02502396: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT02502396 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 265 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502396 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 265 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients. The secondary objectives are to evaluate outcomes such as recurrent VTE, stroke and bleeding for cancer patients on rivaroxaban.
Primary Outcome
Proportion (95% confidence interval (CI)) of cancer patients who were on rivaroxaban with indication of VTE obtained among cancer patients who were on rivaroxaban. Analyses made among patients with VTE summarizing practice patterns of rivaroxaban by means, SDs, and ranges for continuous variables (e.g. platelet counts before a procedure) and the counts and percentages for categorical variables (e.g. stopping rivaroxaban before a procedure, stopping rivaroxaban when the platelets dropped \< 50K,
Interventions
- OTHER Retrospective Chart Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2022-03-15 |
What the finished NCT02502396 record still lists
NCT02502396 is an observational study that tracks outcomes without assigning an intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Retrospective Chart Review is the first listed.
NCT02502396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02502396 about?
NCT02502396 is a clinical study titled "Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center". The primary objective of this study is to evaluate the practice patterns of rivaroxaban usage invenous-thromboembolism (VTE) and non-valvular atrial fibrillation (NVAF) in cancer patients. The secondary objectives are to evaluate outcomes such as recurrent VTE, stroke and bleeding for cancer patien...
What is the current status of trial NCT02502396?
This trial is currently completed. The enrollment target is 265 participants. The study started on 2015-09-28. Estimated completion is 2022-03-15.
What interventions are being tested in trial NCT02502396?
The interventions under investigation include: Retrospective Chart Review (OTHER).
Who is sponsoring clinical trial NCT02502396?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI